CIK 0001095981 · Non-accelerated filer<br>Smaller reporting company
CERENOME, INC.
Sign in to watch- Ticker
- CNSY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330827593
- Phone
- 737.255.7194
- Business address
- 6420 LEVIT GREEN BOULEVARD, SUITE 310, HOUSTON, TX, 77021
- Former names
- PLUS THERAPEUTICS, INC., CYTORI THERAPEUTICS, INC., MACROPORE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-15 | KESTEN STEVEN Exec VP and Chief MO | Option exercise · Subscription Rights (Right to Buy) | −200 | 0 | ||
| 2016-06-15 | KESTEN STEVEN Exec VP and Chief MO | Option exercise · Warrants (Right to Buy) | +100 | 100 | ||
| 2016-06-15 | Girao Tiago VP & Chief Financial Officer | Option exercise | +5,667 | 14,084 | ||
| 2016-06-15 | Girao Tiago VP & Chief Financial Officer | Option exercise · Subscription Rights (Right to Buy) | −5,667 | 0 | ||
| 2016-06-15 | Girao Tiago VP & Chief Financial Officer | Option exercise · Warrants (Right to Buy) | +2,833 | 2,833 | ||
| 2016-06-15 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise | +2,500 | 4,500 | ||
| 2016-06-15 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise · Subscription Rights (Right to Buy) | −2,500 | 0 | ||
| 2016-06-15 | HARRIS JOHN DAVID VP and GM Cell Therapy | Option exercise · Warrants (Right to Buy) | +1,250 | 1,250 | ||
| 2016-06-15 | HAYDEN JEREMY B. General Counsel & VP of BD | Option exercise | +1,896 | 3,643 | ||
| 2016-06-15 | HAYDEN JEREMY B. General Counsel & VP of BD | Option exercise · Subscription Rights (Right to Buy) | −1,896 | 0 | ||
| 2016-06-15 | HAYDEN JEREMY B. General Counsel & VP of BD | Option exercise · Warrants (Right to Buy) | +948 | 948 | ||
| 2016-06-15 | HEDRICK MARC H President and CEO | Option exercise | +41,305 | 44,292 | ||
| 2016-06-15 | HEDRICK MARC H President and CEO | Option exercise · Subscription Rights (Right to Buy) | −41,305 | 0 | ||
| 2016-06-15 | HEDRICK MARC H President and CEO | Option exercise · Warrants (Right to Buy) | +20,652 | 20,652 | ||
| 2016-06-14 | RICKEY DAVID Director | Purchase | +5,000 | $2.10 | $11K | 55,226 |
| 2016-06-14 | Naughton Gail K Director | Purchase | +1,000 | $2.10 | $2K | 2,400 |
| 2016-05-13 | HARRIS JOHN DAVID VP and GM Cell Therapy | Purchase | +2,000 | $2.71 | $5K | 2,000 |
| 2016-03-09 | RICKEY DAVID Director | Purchase | +50,000 | $0.19 | $9K | 270,059 |
| 2016-03-09 | RICKEY DAVID Director | Purchase | +100,000 | $0.19 | $19K | 753,385 |
| 2016-01-28 | Girao Tiago VP & Chief Financial Officer | Grant or award | +35,250 | 126,250 |
Page 15 of 53 · 1,048 trades